EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020

Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020

GAITHERSBURG, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 20, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2019, recent business developments, financial outlook for full year 2020, and revenue guidance for the first quarter of 2020.

This conference call can be accessed live by telephone or by webcast:

Live Teleconference Information:

Dial in number – toll-free: (855) 766-6521

Dial in number – toll: (262) 912-6157

Conference ID: 7270157
 
Live Webcast Information:

Visit for the live webcast feed.

A replay of the call can be accessed on Emergent’s website under “.”

About Emergent BioSolutions

As a global life sciences company whose mission is to protect and enhance life, we provide solutions that target public health threats. Through our specialty products and services as well as our social responsibility efforts, we aspire to build healthier, safer communities and deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. For more information visit . Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

 

Media Contact:

Lynn Kieffer

Vice President, Corporate Communications

240-631-3391

 



EN
03/02/2020

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Secures $62.4 Million Contract Modification for ...

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS) for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been ma...

June 23, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Addition to Russell 3000® Index

Emergent BioSolutions Announces Addition to Russell 3000® Index GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market , effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes. “Inclusion in the Russell 3000® Index is an important milestone in Emergent’s ongoing transformation,” said Joe Papa, president and chief executive officer of Emergent BioSolutions. “This recognition reflects the positive momentum we are buildin...

June 20, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Supports Victoria's Voice Foundation’s National ...

Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria’s Voice Foundation to rally Americans to help save lives from the opioid epidemic on , which honors the late Victoria Siegel and others ...

June 5, 2025 1 EN
Free Trial
EBS Emergent BioSol...

Emergent Biosolutions Inc: 1 director

A director at Emergent Biosolutions Inc bought 60,000 shares at 5.830USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

EBS EMERGENT BIOSOLUTIONS INC.
05/15/25 May 15, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences: RBC Global Healthcare Conference (New York, New York)Fireside chat on Tuesday, May 20 at 3:35 pm ETVirtual attendees can participate via  Goldman Sachs Leveraged Finance Conference, May 29, 2025 (Dana Point, California) Benchmark’s 5th Annual Healthcare House Call Virtual Investor ConferencePresentation on...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch